Of the pancreas.

Of the pancreas.the progression-free survival advantage Sutent in patients with pancreatic neuroendocrine tumorsPfizer Inc. Announced final results from a randomized phase 3 trial of Sutent in patients with advanced neuroendocrine tumors of the pancreas, a type of cancer the the hormone-producing area of the pancreas. Sunitinib more than doubled the time patients with pancreatic neuroendocrine … [Read more…]